James Waldron

This discussion features Darren Incorvaia, a Staff writer at Fierce Biotech, who sheds light on how NIH funding cuts impact drug discovery. Fraser Kansteiner, a reporter/editor at Fierce Pharma, dives into the shifting dynamics within FDA vaccine policies. Angus Liu and Eric Sagonowsky provide insights on FDA leadership changes and their implications. The panel also evaluates the cautious optimism seen at the Jefferies Healthcare Conference, while Heather Landi and Paige Minemyer analyze the challenges providers face and the evolving role of AI in healthcare.

James Waldron, a journalist from Fierce Biotech, brings insights on the biggest clinical trial failures of 2024. He highlights the disappointing results from major companies like AbbVie and Pfizer, particularly in trials for schizophrenia and Duchenne muscular dystrophy. The discussion delves into lessons learned from these setbacks and the human impact of failed trials. Waldron and Gabrielle Masson also explore the ongoing challenges the industry faces and the crucial need for innovative treatments to improve patient outcomes.